A novel series of mutilin 14-carbamates has been discovered as a result of
structure-activity studies on the naturally occurring antibiotic pleuromuti
lin (1). In particular, the 4-methoxybenzoylcarbamate, SE-222734 (15o) disp
lays potent antibacterial activity against a number of bacterial pathogens
which are resistant to currently used agents and shows enhanced metabolic s
tability when compared to earlier pleuromutilin derivatives. Such derivativ
es therefore have the potential to provide a new class of antibacterial age
nts for human therapy which address the threat of bacterial resistance. (C)
2001 Elsevier Science Ltd. All rights reserved.